Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease

Lee, Bor‐Jen; Huang, Yann-Chang; Chen, Shu-Ju; Lin, Ping-Ting

doi:10.1016/j.nut.2011.06.004

Cited by 136 publications

(102 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus far, it has been established that CoQ 10 delivers therapeutic benefits in some heart conditions, including heart failure and coronary artery disease (Lee et al, 2012a(Lee et al, , 2012bLittarru and Tiano, 2010;Singh et al, 1998;Smith and Murphy, 2010). A human clinical study investigating the relation between CoQ 10 and inflammation in patients with coronary artery disease reports that oral supplementation of CoQ 10 at 150 mg/day results in decreased expression of inflammatory markers, that is, C-reactive protein, IL-6, and homocysteine (Lee et al, 2012b).…”

Section: Introductionmentioning

confidence: 99%

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Sikorska

Lanthier

Miller

et al. 2014

Neurobiology of Aging

View full text Add to dashboard Cite

Although the support for the use of antioxidants, such as coenzyme Q 10 (CoQ 10 ), to treat Parkinson's disease (PD) comes from the extensive scientific evidence, the results of conducted thus far clinical trials are inconclusive. It is assumed that the efficacy of CoQ 10 is hindered by insolubility, poor bioavailability, and lack of brain penetration. We have developed a nanomicellar formulation of CoQ 10 (Ubisol-Q 10 ) with improved properties, including the brain penetration, and tested its effectiveness in mouse MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) model with the objectives to assess its potential use as an adjuvant therapy for PD. We used a subchronic MPTP model (5-daily MPTP injections), characterized by 50% loss of dopamine neurons over a period of 28 days. Ubisol-Q 10 was delivered in drinking water. Prophylactic application of Ubisol-Q 10 , started 2 weeks before the MPTP exposure, significantly offset the neurotoxicity (approximately 50% neurons died in MPTP group vs. 17% in MPTP+ Ubisol-Q 10 group by day 28). Therapeutic application of Ubisol-Q 10 , given after the last MPTP injection, was equally effective. At the time of intervention on day 5 nearly 25% of dopamine neurons were already lost, but the treatment saved the remaining 25% of cells, which otherwise would have died by day 28. This was confirmed by cell counts, analyses of striatal dopamine levels, and improved animals' motor skill on a beam walk test. Similar levels of neuroprotection were obtained with 3 different Ubisol-Q 10 concentrations tested, that is, 30 mg, 6 mg, or 3 mg CoQ 10 /kg body weight/day, showing clearly that high doses of CoQ 10 were not required to deliver these effects. Furthermore, the Ubisol-Q 10 treatments brought about a robust astrocytic activation in the brain parenchyma, indicating that astroglia played an active role in this neuroprotection. Thus, we have shown for the first time that Ubisol-Q 10 was capable of halting the neurodegeneration already in progress;

show abstract

Section: Introductionmentioning

confidence: 99%

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Sikorska

Lanthier

Miller

et al. 2014

Neurobiology of Aging

View full text Add to dashboard Cite

show abstract

“…Therefore, oral supplementation with CoQ10 (1) increased ubiquinol10 (2) in the plasma and lipoproteins thereby improving the resistance of LDL to radical oxidation [22]. CoQ10 (1) supplementation reduced the oxidative stress and inflammatory marker IL-6 while increasing antioxidant enzyme activity in atherosclerosis patients [23,24].…”

Section: Atherosclerosismentioning

confidence: 99%

Co-enzyme Q10 (Ubiquinone): It's Implication in Improving the Life Style of the Elderly

Motohashi¹,

Gallagher²,

Venugopalan³

et al. 2018

Med Clin Rev

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ10) (1) is lipid-soluble and an important mitochondrial redox component, endogenously produced antioxidant in the human organisms. CoQ10 (1) plays an important role in the production of cellular energy, strengthens the immune system and acts as a free radical scavenger. Aging, poor eating habits, infections and stress affect the amounts of CoQ10 (1) in the humans. As human beings age, they begin to lose the ability to synthesize CoQ10 (1) from food resulting in its deficiency. CoQ10 (1) facilitates the production of adenosine triphosphate (ATP) in the mitochondria by participating in redox reactions within the electron transport chain. Cardiovascular disease deaths in elders are 80% in males and 75% in females. The average age of death from cardiovascular diseases in the developing world is 68 years and in developed world it is 80 years. Cardiovascular disease onset is 7-10 years earlier in men as compared to women. A low level of myocardial CoQ10 (1) is related to the severity of heart failure. Long-term CoQ10 (1) treatment of patients with chronic heart failure is safe and reduces major adverse cardiovascular complications.

show abstract

“…, where i = 1, 2, 3 … m (m is the number of intervals) (4) In this study interval SR was used for the same reasons as iPLS method. In the latter equation degree of freedom is not used for R 2 , but this equally influences all intervals.…”

Section: Interval Selectivity Ratio (Isr)mentioning

confidence: 99%

“…The reason of the wide popularity of CoQ10 is that it could help in prevention and treatment of many diseases, such as mitochondrial disease [2] and breast cancer [3] and it can decrease oxidative stress and increase antioxidant enzyme activity in patients with coronary artery disease [4]. Other studies suggest that CoQ10 may improve the ejection fraction in patients with congestive heart failure [5].…”

Section: Introductionmentioning

confidence: 99%

Quantitative determination of coenzyme Q10 from dietary supplements by FT-NIR spectroscopy and statistical analysis

et al. 2015

View full text Add to dashboard Cite

A novel, time-and money-sparing method has been developed and validated for the quantitative determination of coenzyme Q10 (CoQ10) from several dietary supplements. FT-NIR spectroscopy was applied for the examination, and a calibration model was built by partial leastsquare regression (PLS-R) using fifty dietary supplements. The combination of FT-NIRS and multivariate calibration methods is a very fast and simple way to replace the commonly used HPLC-UV method; because in contrast with the traditional techniques sample pretreatment and reagents are not required and no wastes are produced.The calibration models could be improved by different variable selection techniques (for instance interval PLS, interval selectivity ratio, genetic algorithm), which are very fast and userfriendly. The R 2 (goodness of calibration) and Q 2 (goodness of validation) of the variable selected models are highly increased, the R 2 values being over 0.90 and the Q 2 values being over 0.86 in every case. Five-fold cross-validation and external validation were applied. The developed method(s) could be used by quality assurance laboratories for routine measurement of coenzyme Q10 products.

show abstract

Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease

Cited by 136 publications

References 36 publications

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Co-enzyme Q10 (Ubiquinone): It's Implication in Improving the Life Style of the Elderly

Quantitative determination of coenzyme Q10 from dietary supplements by FT-NIR spectroscopy and statistical analysis

Contact Info

Product

Resources

About